Brief: Poseida Therapeutics Provides Updates And Financial Results For The Fourth Quarter And Full Year 2023

Poseida Therapeutics

07/03/2024 21:15

March 7 (Reuters) - Poseida Therapeutics Inc  PSTX.O :
    * POSEIDA THERAPEUTICS PROVIDES UPDATES AND FINANCIAL
RESULTS FOR
THE FOURTH QUARTER AND FULL YEAR 2023
    * POSEIDA THERAPEUTICS INC - INITIATED CLINICAL TRIAL OF
PHASE 1
P-CD19CD20-ALLO1, COMPANY'S FIRST ALLOGENEIC DUAL CAR-T PROGRAM
    * POSEIDA - LEAD ASSET P-BCMA-ALLO1 PHASE 1 CLINICAL TRIAL
DATA
PRESENTED AT ASH 2023 SHOWED 82% ORR & FAVORABLE EMERGING SAFETY
AND RELIABILITY PROFILE
    * POSEIDA - BRENT WARNER, WHO HAS SERVED AS CO'S PRESIDENT,
GENE
THERAPY, WILL DEPART POSEIDA TO PURSUE AN EXTERNAL CAREER
OPPORTUNITY EFFECTIVE APRIL 1

Source text for Eikon:  ID:nPn2XXsDla 
Further company coverage:  PSTX.O